Immune treatment using exosome therapy for severe COVID-19
Part of Infections, Lungs & breathing clinical trials.
This trial tests whether immune-supporting treatment made from exosomes can help people with critically severe COVID-19 and lung damage. If you qualify, you may receive this therapy as part of the study to see if it improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be hospitalized with critically ill COVID-19.
- Your COVID-19 must be at least “severe” (WHO severity level 4 or higher).
- You must have lung dysfunction consistent with ARDS (a serious lung condition from COVID-19).
- You must weigh more than 50 kg.
- You (or your legal representative) must be able to give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether donated “recovered patient” plasma (antibodies from people who had COVID-19) can improve outcomes for people hospitalized with COVID-19. It focuses on patients early in their illness who need a small amount of oxygen.
This study looks at how the body's immune system reacted to COVID-19 in people who had either severe or mild cases. The goal is to learn more about a specific part of the immune response (called IFN-I) to better understand the disease.
This study collects immune cells from people who recovered from COVID-19 and may use them to boost protection against SARS-CoV-2. It’s for hospitalized patients who already show a certain level of COVID-19 fighting immune response.
This trial studies whether a new treatment using stem cells from healthy donors can help people with severe or critical COVID-19. The goal is to see if it reduces inflammation and helps you recover faster.
This early-phase study tests immune cells from a matched family donor (made to target the COVID-19 virus) to see if they can help people with mild-to-moderate COVID-19 who are hospitalized and at higher risk for getting sicker. It aims to check safety first and also look for signs of benefit.
This trial is testing a new medicine made from tiny particles called exosomes that target a protein called HLA-G. The study is being done in healthy people to check if the medicine is safe and how the body handles it.
Hear when a new COVID-19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.